TiGenix in licensing deal with Takeda

Publication date : 05/07/2016

TiGenix NV (Euronext Brussels: TIG) and Takeda Pharmaceutical Company Limited (TSE: 4502) have entered into an exclusive ex-U.S. license, development and commercialization agreement for TiGenix’s product Cx601, a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn’s disease.

TiGenix will receive an upfront cash payment of €25 million. TiGenix will be eligible to receive additional regulatory and sales milestone payments for up to a potential total of €355 million and double digit royalties on net sales by Takeda. The first anticipated milestone payment is €15 million upon obtaining the Marketing Authorization of Cx601 in the European Economic Area (EEA). In addition, Takeda will make an equity investment of €10 million in the share capital of TiGenix within the next 12 months.

TiGenix NV is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.

Takeda Pharmaceutical Company Limited is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas.

Follow this link to download TiGenix’s press release from TiGenix’s website.

GODDYN, a legal consulting firm with a strong focus on R&D, assisted TiGenix in this licensing transaction with Takeda for TiGenix’s product Cx601.

For more information, please contact:

Bart GODDYN

T: +32 486 62 64 84

bart.goddyn@goddyn.eu

About GODDYN

GODDYN BVBA is a legal consulting firm that provides a broad range of transactional and advisory capabilities to both Belgian and international clients, ranging from small-sized companies to multinational organizations in sectors such as Pharma, Life Sciences, Health Care, Food and Nutrition, Manufacturing, Industrial Services, ICT. Clients include life sciences companies, institutions, university spin-outs, developers, manufacturers, suppliers and investors. GODDYN focuses on technology and advises clients on their R&D and Business Development activities, including on intellectual property protection and strategy, clinical trials, licensing, manufacturing, commercial exploitation. GODDYN's mission is to provide high quality, creative and result-oriented legal services to its business clients, understanding and addressing their needs and doing so in a fair, timely and cost effective manner. For more information, please visit: http://www.goddyn.eu.